title: [Prevention of progression and regression of target organ damage. Future strategies].
abstract: Treatment with renin-angiotensin system blockers (angiotensin converting-enzyme inhibitors and AT1 receptor antagonists) has shown clear benefits in distinct stages of cardiovascular disease (CVD). This treatment lowers blood pressure and prevents the appearance of markers of subclinical disease such as microalbuminuria, reduces cardiovascular and renal episodes in patients with subclinical lesions and prolongs survival in patients with clinical disease or organ dysfunction. Despite this unquestionable benefit, the residual risk in patients receiving these treatments often continues to be highly elevated and consequently strategies to reduce this risk are required. The present article reviews the options that may help to reduce cardiovascular disease. In addition to renin-angiotensin system blockers, these treatments include primary prevention in healthy individuals, stricter therapeutic goals, comprehensive risk control, more complete blocking of the renin-angiotensin system and the use of drugs with synergistic protective mechanisms.
authors: Unidad de Hipertensión, Servicio de Medicina Interna, Hospital Mútua Terrassa, Universidad de Barcelona, Barcelona, Spain. adelasierra@mutuaterrassa.es
authors: A
authors: A
authors: de la Sierra
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D018450:Disease Progression; D005544:Forecasting; D006801:Humans; D009102:Multiple Organ Failure / Q000517:prevention & control*; D012084:Renin-Angiotensin System / Q000187:drug effects